New York Peptide Research Regulatory Overview
Federal and state regulatory context for research-grade peptide compounds in New York. Informational summary for scientific researchers and research institutions.
Disclaimer: This page provides general regulatory context for informational purposes only and does not constitute legal advice. Researchers should consult applicable federal and state regulations and qualified legal counsel before making any decisions based on this content.
Federal Regulatory Context
Federal regulation of research chemicals involves FDA oversight of commercial research chemical sale under general commerce and safety regulations, and DEA jurisdiction under the Controlled Substances Act for specifically scheduled compounds. BPC-157, TB-500, GHK-Cu, NAD+, Epithalon, and the other research peptide compounds commonly available from research suppliers are not currently listed under any federal DEA controlled substance schedule. These compounds are available for legitimate in vitro laboratory research procurement and use without the DEA registration and record-keeping requirements that apply to scheduled controlled substances.
New York State Context
New York Public Health Law Article 33 establishes state-level controlled substance scheduling in five schedules that track federal CSA scheduling. New York does not currently impose additional scheduling restrictions on unscheduled research-grade peptide compounds beyond those established by federal law. New York also has specific regulations governing drug laboratories and biosafety under the New York State Department of Health, which apply to institutional research settings. Researchers at New York institutions should consult institutional compliance offices and qualified legal counsel for guidance on applicable regulations.
Research Overview
New York is one of the leading biomedical research states in the nation, hosting major research institutions including Rockefeller University, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Columbia University Irving Medical Center, New York University Grossman School of Medicine, and Cold Spring Harbor Laboratory. Research-grade peptide compounds for in vitro laboratory research are regulated at the federal level under FDA and DEA jurisdiction. New York Public Health Law Article 33 (Controlled Substances Act) establishes state scheduling that tracks federal CSA scheduling for controlled substances but does not include the unscheduled research-grade peptide compounds such as BPC-157, TB-500, GHK-Cu, NAD+, and Epithalon within its scheduling framework. New York research institutions have well-established compliance infrastructure for research chemical procurement and management.
- •Rockefeller University
- •Memorial Sloan Kettering Cancer Center
- •Columbia University Irving Medical Center
Commonly Researched Compounds
Research-grade compounds commonly procured by institutions in New York for in vitro and preclinical research programs.
Frequently Asked Questions
Legal Disclaimer
The information on this page is provided for general informational and educational purposes only. It does not constitute legal advice and should not be relied upon as such. Laws and regulations governing research chemicals, peptides, and related compounds vary by jurisdiction and are subject to change. Researchers and organizations should consult a qualified legal professional familiar with federal and state law applicable to their specific situation before making any decisions based on this content. Spartan Peptides does not provide legal counsel and makes no representations regarding the legal status of any compound in any specific jurisdiction.
Explore All Research-Grade Compounds
Browse the full Spartan Peptides research compound catalog. All compounds are research-grade, supplied as lyophilized powder with certificate of analysis, for in vitro laboratory research use only.